Details for Patent: 10,111,890

Which drugs does patent 10,111,890 protect, and when does it expire?

Patent 10,111,890 protects NUZYRA and is included in one NDA.

This patent has twenty-one patent family members in thirteen countries.

Summary for Patent: 10,111,890

Title:	9-aminomethyl minocycline compounds and uses thereof
Abstract:	Methods and compositions for using a tetracycline compound to treat bacterial infections are described. In one embodiment, for example, the invention provides a method of treating a subject for an infection, comprising administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein the 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline is administered orally at a dose of about 450 mg per day for two consecutive days, then at a dose of about 300 mg per day for 5 or more days.
Inventor(s):	Tanaka; S. Ken (Bellevue, WA), Tzanis; Evangelos L. (Newtown Square, PA), Garrity-Ryan; Lynne (Melrose, MA), Manley; Amy L. (Phoenixville, PA)
Assignee:	Paratek Pharmaceuticals, Inc. (Boston, MA)
Application Number:	15/667,683
Patent Claim Types: see list of patent claims	Use; Delivery; Dosage form;

Drugs Protected by US Patent 10,111,890

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Paratek Pharms Inc	NUZYRA	omadacycline tosylate	TABLET;ORAL	209816-001	Oct 2, 2018		RX	Yes	Yes						TREATMENT OF SUBJECTS HAVING BACTERIAL SKIN OR SKIN STRUCTURE INFECTION

International Family Members for US Patent 10,111,890

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2017305409
Australia	2022203977
Brazil	112019001948
Canada	3031790
China	109789153
European Patent Office	3493813
Japan	2019524767